Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.59 |
| ▸ | RIPK3 | Q9Y572 | 3/20 | 0.59 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.59 |
| ▸ | MET | P08581 | 17/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | AXL | P30530 | 6/20 | 0.52 |
| ▸ | TYRO3 | Q06418 | 4/20 | 0.50 |
| ▸ | MERTK | Q12866 | 3/20 | 0.50 |
| ▸ | MST1R | Q04912 | 2/20 | 0.50 |
| ▸ | LCK | P06239 | 2/20 | 0.49 |
| ▸ | KIT | P10721 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | FLT3 | P36888 | 2/20 | 0.49 |
| ▸ | PLK4 | O00444 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | PRKACA | P17612 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25367016 | 0.92 | RIPK2 (0.60) | RIPK1RIPK3RIPK2METCYP3A4 | |
| SCHEMBL25366637 | 0.91 | RIPK1 (0.60) | RIPK1RIPK3RIPK2METCYP3A4 | |
| SCHEMBL26317365 | 0.90 | RIPK3 (0.74) | RIPK1RIPK3RIPK2METCYP3A4 | |
| SCHEMBL25365777 | 0.88 | RIPK2 (0.58) | RIPK1RIPK3RIPK2METCYP3A4 | |
| SCHEMBL25366374 | 0.88 | RIPK2 (0.58) | RIPK1RIPK3RIPK2METCYP3A4 | |
| SCHEMBL25366935 | 0.85 | MET (0.70) | RIPK1RIPK3RIPK2METAXL | |
| SCHEMBL26317372 | 0.83 | RIPK3 (0.73) | RIPK1RIPK3RIPK2METCYP3A4 | |
| SCHEMBL25364760 | 0.82 | RIPK3 (0.76) | RIPK1RIPK3RIPK2METCYP3A4 | |
| SCHEMBL25366910 | 0.81 | RIPK3 (0.75) | RIPK1RIPK3RIPK2METCYP3A4 | |
| SCHEMBL26317345 | 0.81 | RIPK3 (0.75) | RIPK1RIPK3RIPK2METCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023156864-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023156864-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-24 | — | — | WO | disclosed |
| US-20230257364-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257364-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257364-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257364-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | MERTK, MET, AXL | RIPK1 1682/4885RIPK3 1229/4885RIPK2 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.